CN105535947A - Pharmaceutical composition for treating II-type diabetes and preparation method of pharmaceutical composition - Google Patents
Pharmaceutical composition for treating II-type diabetes and preparation method of pharmaceutical composition Download PDFInfo
- Publication number
- CN105535947A CN105535947A CN201610038013.7A CN201610038013A CN105535947A CN 105535947 A CN105535947 A CN 105535947A CN 201610038013 A CN201610038013 A CN 201610038013A CN 105535947 A CN105535947 A CN 105535947A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- treatment
- patuletin
- type iidiabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y117/00—Oxidoreductases acting on CH or CH2 groups (1.17)
- C12Y117/03—Oxidoreductases acting on CH or CH2 groups (1.17) with oxygen as acceptor (1.17.3)
- C12Y117/03002—Xanthine oxidase (1.17.3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01004—Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
Abstract
The invention discloses a pharmaceutical composition for treating II-type diabetes and a preparation method of pharmaceutical composition. The pharmaceutical composition comprises the following ingredients in parts by weight: 80-150 parts of a crude fiber mixture, 60-90 parts of phycocyanobilin, 50-80 parts of patuletin, 38-76 parts of diosgenin, 35-70 parts of rutin, 16-30 parts of polyethylene glycol, 15-24 parts of pyridoxine, 12-18 parts of flavonoid glycosides, 10-16 parts of linoleic acid, 10-15 parts of sciadopitysin, 8-13 parts of kaempferol, 8-12 parts of quercetin, 7-11 parts of glutamic acid, 6-10 parts of lysine, 5-10 parts of tannin, 5-8 parts of flunarizine, 4-7 parts of thiamine and 2-6 parts of mixed enzyme. The pharmaceutical composition disclosed by the invention is a combination of traditional Chinese medicine and western medicines, effectively reduces the blood sugar and improves the glucose tolerance level of a muscle body on the basis of regulating the normal diet, regulates various abnormal indicators of the muscle body, enhances the tolerance of long-term drug use of a diabetic patient and reduces drug side effects. The pharmaceutical composition disclosed by the invention is simple in preparation process and convenient to use and has good clinical popularization significance.
Description
Technical field
The present invention relates to diabetic technical field, specifically relate to a kind of pharmaceutical composition for the treatment of type Ⅱdiabetes mellitus and preparation method thereof.
Background technology
Diabetes be a kind of common take hyperglycemia as the chronic metabolic disease of feature, be due to the various virulence factor of inherited genetic factors, immunologic function disorder, infected by microbes and toxin thereof, free radical toxin, Nervous and Mental Factors etc. act on body cause hypoinsulinism, insulin resistant etc. and cause a series of metabolism disorder syndrome such as sugar, protein, fat, water and eletrolytes, it is one of large difficult and complicated illness in the world three, add up according to available data, the existing diabetics of China about 5,600 ten thousand people, and with annual about 2,000,000 speed increment.Diabetes have become the third-largest noninfectious of the harm humans health being only second to cancer and cardiovascular disease, therefore, find effective Therapeutic Method and just seem particularly important.Diabetes are mainly divided into 1 type and 2 types: type 1 diabetes, and original name insulin dependent diabetes mellitus (IDDM) mostly occurs at Children and teenager, also can betide the various age.More sharply, in body, insulin is definitely not enough for onset, easily ketoacidosis occurs, and must could obtain satisfactory effect by insulinize, otherwise by threat to life; Patients with NIDDM is based on person in middle and old age, the ability producing insulin in patient body not completely loses, in some patient bodies, insulin even produces too much, but the action effect of insulin is poor, therefore the insulin in patient body is a kind of shortage relatively, the secretion of insulin in body can be stimulated by some oral drugs, but still have some client need use of exogenous insulins to the later stage.Wherein a part of patient is based on insulin resistant, and how fat patient is, and because of insulin resistant, insulin sensitivity declines, and in blood, insulin increases to compensate its insulin resistant, but the hyperglycemia of relative patient, insulin secretion is relative deficiency still.This type of patient's early symptom is not obvious, only has slightly weak, thirsty, is everlasting before clarifying a diagnosis and just trunk and microvascular complication can occurs.Diet Therapy and oral antidiabetic drug is many can be effective.Another part patient, based on defect of insulin secretion, needs supplemented with exogenous insulin clinically.
At present, the clinical treatment of type Ⅱdiabetes mellitus is based on oral western medicine, common are sulphanylureas, biguanides, α glucosidase inhibitor, euglycemic agent, meglitinide Insulin secretagogues etc., long-term taking easily causes dependency and the toxic and side effects of medicine, and accelerate the aging of insulin cell, bring out multiple complications, therefore need a kind of medicine that dietary habit can be regulated to assist and reduce the impact that blood glucose is raised of other multiple symptoms, the blood glucose that can control again patient remains on normal scope, and be beneficial to long-term taking and can not cause large injury to health, this is one of difficult point of development type Ⅱdiabetes mellitus medication.
Summary of the invention
The technical problem that the present invention solves provides a kind of pharmaceutical composition for the treatment of type Ⅱdiabetes mellitus and preparation method thereof.
Technical scheme of the present invention is, a kind of pharmaceutical composition for the treatment of type Ⅱdiabetes mellitus, it is be grouped into by the one-tenth of following weight portion: crude fibre mixture 80-150 part, phycocyanobilin 60-90 part, patuletin 50-80 part, diosgenin 38-76 part, globulariacitrin 35-70 part, Polyethylene Glycol 16-30 part, pyridoxin 15-24 part, flavonoid glycoside 12-18 part, linoleic acid 10-16 part, 7,4',4'''-Trimethylamentoflavone 10-15 part, nimbecetin 8-13 part, Quercetin 8-12 part, glutamic acid 7-11 part, lysine 6-10 part, tannin 5-10 part, flunarizine 5-8 part, thiamine 4-7 part, mixed enzyme 2-6 part.
Further, described crude fibre mixture refers to and cellulose and hemicellulose is obtained according to weight ratio 3:2 mixing, crude fibre can promote gastrointestinal motility, helps digest, and reduces the cholesterol level in blood plasma, prevent and treat hyperlipemia and cardiovascular disease, control body weight, reduce the generation of obesity, thus improve blood glucose reaction of formation, reduce post-prandial glycemia content, help treatment diabetes.
Further, described patuletin preparation method is: fresh Flos Matricariae chamomillae is cleaned up rear pulverizing, be placed in flash extracter, the mass concentration adding 8-12 times amount is 65-75% alcoholic solution, carry out homogenate extraction, extracting solution is obtained after filtration, polyamide drying is added after concentrated, dress post, service property (quality) concentration is 75-95% ethanol elution, collect eluent, concentrate drying obtains patuletin crude product, by crude product through high speed adverse current chromatogram separation and purification, n-hexane-ethyl acetate-methanol-water is solvent system, UV-detector detects, collect patuletin component, carry out vacuum concentration, crystallization, filter, washing is drying to obtain patuletin, patuletin effectively can strengthen body immunity, there is good antioxidant activity, can the cytotoxic activity of T suppression cell, thus well suppress the multiple complications of diabetes, make diabetes over the course for the treatment of from the interference of other symptoms.
Further, described Quercetin is obtained by enzymatic hydrolysis rutin, Quercetin can reduce blood pressure, strengthen capillary resistance, reduce capillary fragility, blood fat reducing, coronary artery dilator, increase the effects such as coronary flow, to diabetes mellitus with coronary heart disease and hypertension symptom have auxiliary therapeutic action, adopt the enzymatic hydrolysis rutin part or all of glycosyl on it, and then prepare the isoquercitin and Quercetin monomer that in plant, content is less in a large number, simple to operate, output capacity is high, with low cost.
Further, the mixture that is made up of according to weight ratio 1:3:4 xanthine oxidase, cellulase, glycosyltransferase of described mixed enzyme.
A kind of preparation method for the treatment of the pharmaceutical composition of type Ⅱdiabetes mellitus is: the crude fibre mixture of described composition by weight, phycocyanobilin, patuletin, diosgenin, globulariacitrin, Polyethylene Glycol, pyridoxin, flavonoid glycoside, linoleic acid, 7,4',4'''-Trimethylamentoflavone, nimbecetin, Quercetin, glutamic acid, lysine, tannin, flunarizine, thiamine are adopted Mechanical Method mix homogeneously, be placed in super micron mill to pulverize, cross 200-300 mesh sieve, add the mixed enzyme of described composition by weight again, namely sealing cold preservation obtain medical treatment the pharmaceutical composition of type Ⅱdiabetes mellitus.
Further, in described pharmaceutical composition, add adjuvant: diluent, wetting agent, disintegrating agent, make capsule by granulation, drying, granulate, screening, filling, polishing, packaging.Described diluent is one or several mixing of mannitol, microcrystalline Cellulose, lactose; Described wetting agent is one or several mixing of magnesium stearate, Pulvis Talci, glyceryl monostearate; Described disintegrating agent is one or several mixing of cross-linked cellulose, polyvinylpolypyrrolidone, glycyl Starch Sodium.
The invention has the beneficial effects as follows: Chinese and western medicine drug combination, the basis regulating normal diet effectively reduces blood glucose and the glucose-tolerant level improving human body, regulate every abnormal index of human body, strengthen the toleration of diabetics long-term prescription, reduce drug side effect, wherein phycocyanobilin, patuletin, diosgenin, globulariacitrin, flunarizine combined effect, can promote metabolism, alleviates blood glucose and raise; Pyridoxin, flavonoid glycoside, linoleic acid, 7,4',4'''-Trimethylamentoflavone, nimbecetin, Quercetin, glutamic acid, lysine, tannin, thiamine comprehensive function can be supplemented needed for human body in time, improve dietary habit, cell activity enhancing and immunocompetence, suppress multiple complications, and there is stronger antioxidation; Pharmaceutical composition preparation technology of the present invention is simple, and side effect is little, easy to use, has good clinical expansion meaning.
Detailed description of the invention
Embodiment 1:
Treating a pharmaceutical composition for type Ⅱdiabetes mellitus, is be grouped into by the one-tenth of following weight portion: 80 parts, crude fibre mixture, phycocyanobilin 60 parts, patuletin 50 parts, diosgenin 38 parts, globulariacitrin 35 parts, Polyethylene Glycol 16 parts, pyridoxin 15 parts, flavonoid glycoside 12 parts, linoleic acid 10 parts, 7,4',4'''-Trimethylamentoflavone 10 parts, nimbecetin 8 parts, Quercetin 8 parts, 7 parts, glutamic acid, lysine 6 parts, tannin 5 parts, flunarizine 5 parts, thiamine 4 parts, mixed enzyme 2 parts.
Wherein, described crude fibre mixture refers to and cellulose and hemicellulose is obtained according to weight ratio 3:2 mixing, crude fibre can promote gastrointestinal motility, helps digest, and reduces the cholesterol level in blood plasma, prevent and treat hyperlipemia and cardiovascular disease, control body weight, reduce the generation of obesity, thus improve blood glucose reaction of formation, reduce post-prandial glycemia content, help treatment diabetes.Described patuletin preparation method is: fresh Flos Matricariae chamomillae is cleaned up rear pulverizing, be placed in flash extracter, the mass concentration adding 8 times amount is 65% alcoholic solution, carry out homogenate extraction, extracting solution is obtained after filtration, polyamide drying is added after concentrated, dress post, service property (quality) concentration is 75% ethanol elution, collect eluent, concentrate drying obtains patuletin crude product, by crude product through high speed adverse current chromatogram separation and purification, n-hexane-ethyl acetate-methanol-water is solvent system, UV-detector detects, collect patuletin component, carry out vacuum concentration, crystallization, filter, washing is drying to obtain patuletin, patuletin effectively can strengthen body immunity, there is good antioxidant activity, can the cytotoxic activity of T suppression cell, thus well suppress the multiple complications of diabetes, make diabetes over the course for the treatment of from the interference of other symptoms.Described Quercetin is obtained by enzymatic hydrolysis rutin, Quercetin can reduce blood pressure, strengthen capillary resistance, reduce capillary fragility, blood fat reducing, coronary artery dilator, increase the effects such as coronary flow, to diabetes mellitus with coronary heart disease and hypertension symptom have auxiliary therapeutic action, adopt the enzymatic hydrolysis rutin part or all of glycosyl on it, and then the isoquercitin that in a large amount of preparation plant, content is less and Quercetin monomer, simple to operate, output capacity is high, with low cost.The mixture that described mixed enzyme is made up of according to weight ratio 1:3:4 xanthine oxidase, cellulase, glycosyltransferase.
The preparation method of this pharmaceutical composition is: the crude fibre mixture of described composition by weight, phycocyanobilin, patuletin, diosgenin, globulariacitrin, Polyethylene Glycol, pyridoxin, flavonoid glycoside, linoleic acid, 7,4',4'''-Trimethylamentoflavone, nimbecetin, Quercetin, glutamic acid, lysine, tannin, flunarizine, thiamine are adopted Mechanical Method mix homogeneously, be placed in super micron mill to pulverize, cross 200 mesh sieves, add the mixed enzyme of described composition by weight again, namely sealing cold preservation obtain medical treatment the pharmaceutical composition of type Ⅱdiabetes mellitus.Add adjuvant in described pharmaceutical composition: diluent, wetting agent, disintegrating agent, make capsule by granulation, drying, granulate, screening, filling, polishing, packaging.Described diluent is one or several mixing of mannitol, microcrystalline Cellulose, lactose; Described wetting agent is one or several mixing of magnesium stearate, Pulvis Talci, glyceryl monostearate; Described disintegrating agent is one or several mixing of cross-linked cellulose, polyvinylpolypyrrolidone, glycyl Starch Sodium.
Embodiment 2:
Treating a pharmaceutical composition for type Ⅱdiabetes mellitus, is be grouped into by the one-tenth of following weight portion: 115 parts, crude fibre mixture, phycocyanobilin 75 parts, patuletin 65 parts, diosgenin 57 parts, globulariacitrin 52.5 parts, Polyethylene Glycol 23 parts, pyridoxin 19.5 parts, flavonoid glycoside 15 parts, linoleic acid 13 parts, 7,4',4'''-Trimethylamentoflavone 12.5 parts, nimbecetin 10.5 parts, Quercetin 10 parts, 9 parts, glutamic acid, lysine 8 parts, tannin 7.5 parts, flunarizine 6.5 parts, thiamine 5.5 parts, mixed enzyme 4 parts.
Wherein, described crude fibre mixture refers to and cellulose and hemicellulose is obtained according to weight ratio 3:2 mixing, crude fibre can promote gastrointestinal motility, helps digest, and reduces the cholesterol level in blood plasma, prevent and treat hyperlipemia and cardiovascular disease, control body weight, reduce the generation of obesity, thus improve blood glucose reaction of formation, reduce post-prandial glycemia content, help treatment diabetes.Described patuletin preparation method is: fresh Flos Matricariae chamomillae is cleaned up rear pulverizing, be placed in flash extracter, the mass concentration adding 10 times amount is 70% alcoholic solution, carry out homogenate extraction, extracting solution is obtained after filtration, polyamide drying is added after concentrated, dress post, service property (quality) concentration is 85% ethanol elution, collect eluent, concentrate drying obtains patuletin crude product, by crude product through high speed adverse current chromatogram separation and purification, n-hexane-ethyl acetate-methanol-water is solvent system, UV-detector detects, collect patuletin component, carry out vacuum concentration, crystallization, filter, washing is drying to obtain patuletin, patuletin effectively can strengthen body immunity, there is good antioxidant activity, can the cytotoxic activity of T suppression cell, thus well suppress the multiple complications of diabetes, make diabetes over the course for the treatment of from the interference of other symptoms.Described Quercetin is obtained by enzymatic hydrolysis rutin, Quercetin can reduce blood pressure, strengthen capillary resistance, reduce capillary fragility, blood fat reducing, coronary artery dilator, increase the effects such as coronary flow, to diabetes mellitus with coronary heart disease and hypertension symptom have auxiliary therapeutic action, adopt the enzymatic hydrolysis rutin part or all of glycosyl on it, and then the isoquercitin that in a large amount of preparation plant, content is less and Quercetin monomer, simple to operate, output capacity is high, with low cost.The mixture that described mixed enzyme is made up of according to weight ratio 1:3:4 xanthine oxidase, cellulase, glycosyltransferase.
The preparation method of this pharmaceutical composition is: the crude fibre mixture of described composition by weight, phycocyanobilin, patuletin, diosgenin, globulariacitrin, Polyethylene Glycol, pyridoxin, flavonoid glycoside, linoleic acid, 7,4',4'''-Trimethylamentoflavone, nimbecetin, Quercetin, glutamic acid, lysine, tannin, flunarizine, thiamine are adopted Mechanical Method mix homogeneously, be placed in super micron mill to pulverize, cross 250 mesh sieves, add the mixed enzyme of described composition by weight again, namely sealing cold preservation obtain medical treatment the pharmaceutical composition of type Ⅱdiabetes mellitus.Add adjuvant in described pharmaceutical composition: diluent, wetting agent, disintegrating agent, make capsule by granulation, drying, granulate, screening, filling, polishing, packaging.Described diluent is one or several mixing of mannitol, microcrystalline Cellulose, lactose; Described wetting agent is one or several mixing of magnesium stearate, Pulvis Talci, glyceryl monostearate; Described disintegrating agent is one or several mixing of cross-linked cellulose, polyvinylpolypyrrolidone, glycyl Starch Sodium.
Embodiment 3:
Treating a pharmaceutical composition for type Ⅱdiabetes mellitus, is be grouped into by the one-tenth of following weight portion: 150 parts, crude fibre mixture, phycocyanobilin 90 parts, patuletin 80 parts, diosgenin 76 parts, globulariacitrin 70 parts, Polyethylene Glycol 30 parts, pyridoxin 24 parts, flavonoid glycoside 18 parts, linoleic acid 16 parts, 7,4',4'''-Trimethylamentoflavone 15 parts, nimbecetin 13 parts, Quercetin 12 parts, 11 parts, glutamic acid, lysine 10 parts, tannin 10 parts, flunarizine 8 parts, thiamine 7 parts, mixed enzyme 6 parts.
Wherein, described crude fibre mixture refers to and cellulose and hemicellulose is obtained according to weight ratio 3:2 mixing, crude fibre can promote gastrointestinal motility, helps digest, and reduces the cholesterol level in blood plasma, prevent and treat hyperlipemia and cardiovascular disease, control body weight, reduce the generation of obesity, thus improve blood glucose reaction of formation, reduce post-prandial glycemia content, help treatment diabetes.Described patuletin preparation method is: fresh Flos Matricariae chamomillae is cleaned up rear pulverizing, be placed in flash extracter, the mass concentration adding 12 times amount is 75% alcoholic solution, carry out homogenate extraction, extracting solution is obtained after filtration, polyamide drying is added after concentrated, dress post, service property (quality) concentration is 95% ethanol elution, collect eluent, concentrate drying obtains patuletin crude product, by crude product through high speed adverse current chromatogram separation and purification, n-hexane-ethyl acetate-methanol-water is solvent system, UV-detector detects, collect patuletin component, carry out vacuum concentration, crystallization, filter, washing is drying to obtain patuletin, patuletin effectively can strengthen body immunity, there is good antioxidant activity, can the cytotoxic activity of T suppression cell, thus well suppress the multiple complications of diabetes, make diabetes over the course for the treatment of from the interference of other symptoms.Described Quercetin is obtained by enzymatic hydrolysis rutin, Quercetin can reduce blood pressure, strengthen capillary resistance, reduce capillary fragility, blood fat reducing, coronary artery dilator, increase the effects such as coronary flow, to diabetes mellitus with coronary heart disease and hypertension symptom have auxiliary therapeutic action, adopt the enzymatic hydrolysis rutin part or all of glycosyl on it, and then the isoquercitin that in a large amount of preparation plant, content is less and Quercetin monomer, simple to operate, output capacity is high, with low cost.The mixture that described mixed enzyme is made up of according to weight ratio 1:3:4 xanthine oxidase, cellulase, glycosyltransferase.
The preparation method of this pharmaceutical composition is: the crude fibre mixture of described composition by weight, phycocyanobilin, patuletin, diosgenin, globulariacitrin, Polyethylene Glycol, pyridoxin, flavonoid glycoside, linoleic acid, 7,4',4'''-Trimethylamentoflavone, nimbecetin, Quercetin, glutamic acid, lysine, tannin, flunarizine, thiamine are adopted Mechanical Method mix homogeneously, be placed in super micron mill to pulverize, cross 300 mesh sieves, add the mixed enzyme of described composition by weight again, namely sealing cold preservation obtain medical treatment the pharmaceutical composition of type Ⅱdiabetes mellitus.Add adjuvant in described pharmaceutical composition: diluent, wetting agent, disintegrating agent, make capsule by granulation, drying, granulate, screening, filling, polishing, packaging.Described diluent is one or several mixing of mannitol, microcrystalline Cellulose, lactose; Described wetting agent is one or several mixing of magnesium stearate, Pulvis Talci, glyceryl monostearate; Described disintegrating agent is one or several mixing of cross-linked cellulose, polyvinylpolypyrrolidone, glycyl Starch Sodium.
The application of pharmaceutical composition of the present invention in treatment type Ⅱdiabetes mellitus:
One, animal pharmacological test:
1, animal model preparation:
Select 150 Adult male rats, body weight 130-180g, to rat injection streptozotocin 50mg/kg, beta Cell of islet is caused to damage, rat is made to produce impaired glucose tolerance, feed high heat food to rat simultaneously, cause Obesity of Rats fast, with hyperlipidemia, hyperinsulinemia and insulin resistance, the single nursing of all animals, to ensure each animal food-intake, causes the animal model of the anthropoid type Ⅱdiabetes mellitus of class after feeding March, 150 rats are divided at random blank group, matched group, experimental group 1, experimental group 2, experimental group 3, often organize 30.
2, medication:
After feeding rats high heat food January, start the method administration adopting gavage, dosage is identical: 1. blank group normal saline gavage every day; 2. matched group adopts metformin to press the dosage gavage of 4.35mg/kgd-1; 3. the dosage gavage of experimental group 1,2, the 3 pharmaceutical composition 1.5g/kgd-1 that uses embodiment 1,2,3 to prepare respectively.
3, test data statistics and result: do not use Beyer Co., Ltd's detecting blood glucose by blood glucose monitoring three times by getting blood system at caudal vein after Rat Fast 8h, every minor tick 30min, be on an empty stomach 3.5-6.2mmol/L according to the normal index of criterion blood glucose, hyperglycemia marker is empty stomach 6.3-10.0mmol/L, superelevation blood glucose target is empty stomach more than 10.0mmol/L, and testing result is as following table:
| Group | Rat quantity (only) | Blood glucose normal index Mus number | Hyperglycemia marker Mus number | Superelevation blood glucose target Mus number |
| Blank group | 30 | 0 | 14 | 16 |
| Matched group | 30 | 12 | 17 | 1 |
| Experimental group 1 | 30 | 23 | 7 | 0 |
| Experimental group 2 | 30 | 29 | 1 | 0 |
| Experimental group 3 | 30 | 26 | 4 | 0 |
As can be seen from the above table, the blood glucose of pharmaceutical composition to animal for the treatment of type Ⅱdiabetes mellitus that prepared by the present invention has good control action.
As can be seen from the above table, the blood glucose of pharmaceutical composition to animal for the treatment of type Ⅱdiabetes mellitus that prepared by the present invention has good control action.
Two, clinical trial:
1, case-data: inventor have collected patients with NIDDM 90 example, all from department of endocrinology outpatient service, at 35 ~ 75 years old age, is divided into test group 1, test group 2, test group 3 respectively, often organizes 30 people, the performance of diabetes sign is without individual variation.
2, test method and criterion:
A. be divided into the patient of test group 1, test group 2, test group 3 to take the capsule of the embodiment of the present invention 1, embodiment 2, embodiment 3 preparation respectively, every day 2 times 4 weeks is a course for the treatment of.
B. the normal index criterion of blood glucose: 3.9-6.1mmol/L on an empty stomach, 2 hours is after the meal 3.9-7.8mmol/L, and the blood glucose of diabetics is greater than 7.8mmol/L on an empty stomach, within 2 hours after the meal, is greater than 11.1mmol/L.
3, criterion of therapeutical effect and therapeutic outcome
3.1 criterions of therapeutical effect:
Judge according to " type Ⅱdiabetes mellitus disease diagnosis and efficacy assessment standard ": 1. patient blood glucose recovers normally, clinical symptom disappearance and lasting more than three months persons be as effective; 2. patient blood glucose recovers normally, the clinical symptoms person of having clear improvement is effective; 3. the abnormal also clinical symptoms of patient blood glucose is invalid without improving or adding severe one.
3.2 therapeutic outcomes:
| Group | Case load | Effective | Effectively | Invalid | Effective percentage % |
| Test group 1 | 30 | 16 | 10 | 4 | 86.7 |
| Test group 2 | 30 | 23 | 6 | 1 | 96.7 |
| Test group 3 | 30 | 18 | 9 | 3 | 90.0 |
In process of the test, all patients have no other obvious adverse reaction, and the total effective rate that the present invention is used for the treatment of type Ⅱdiabetes mellitus is 86.7%, the value of the clinical practice had.
Although describe with reference to its specific embodiments and illustrate the present invention, those of skill in the art will recognize that and can make various change, amendment and replacement when not deviating from the spirit and scope of the present invention to it.Such as, owing to being treated the change of the responding ability of the people of particular condition, the effective dose beyond the preferred dose as above set forth may be suitable for.Similarly, the pharmacology observed responds may basis and rely on selected particular active compounds or whether there is pharmaceutical carrier and preparation type and mode of administration used and become, and changes or difference according to this kind of expection that object of the present invention and practice are contemplated in result.Therefore, the invention is intended to only by following patent requirement scope restriction and these claim should explain as broadly as possible in rational degree.
Claims (10)
1. treat the pharmaceutical composition of type Ⅱdiabetes mellitus for one kind, it is characterized in that, it is be grouped into by the one-tenth of following weight portion: crude fibre mixture 80-150 part, phycocyanobilin 60-90 part, patuletin 50-80 part, diosgenin 38-76 part, globulariacitrin 35-70 part, Polyethylene Glycol 16-30 part, pyridoxin 15-24 part, flavonoid glycoside 12-18 part, linoleic acid 10-16 part, 7,4',4'''-Trimethylamentoflavone 10-15 part, nimbecetin 8-13 part, Quercetin 8-12 part, glutamic acid 7-11 part, lysine 6-10 part, tannin 5-10 part, flunarizine 5-8 part, thiamine 4-7 part, mixed enzyme 2-6 part.
2. a kind of pharmaceutical composition for the treatment of type Ⅱdiabetes mellitus as claimed in claim 1, is characterized in that, described crude fibre mixture refer to by cellulose and hemicellulose obtained according to weight ratio 3:2 mixing.
3. a kind of pharmaceutical composition for the treatment of type Ⅱdiabetes mellitus as claimed in claim 1, it is characterized in that, described patuletin preparation method is: fresh Flos Matricariae chamomillae is cleaned up rear pulverizing, be placed in flash extracter, the mass concentration adding 8-12 times amount is 65-75% alcoholic solution, carry out homogenate extraction, extracting solution is obtained after filtration, polyamide drying is added after concentrated, dress post, service property (quality) concentration is 75-95% ethanol elution, collect eluent, concentrate drying obtains patuletin crude product, by crude product through high speed adverse current chromatogram separation and purification, n-hexane-ethyl acetate-methanol-water is solvent system, UV-detector detects, collect patuletin component, carry out vacuum concentration, crystallization, filter, washing is drying to obtain patuletin.
4. a kind of pharmaceutical composition for the treatment of type Ⅱdiabetes mellitus as claimed in claim 1, it is characterized in that, described Quercetin is obtained by enzymatic hydrolysis rutin.
5. a kind of pharmaceutical composition for the treatment of type Ⅱdiabetes mellitus as claimed in claim 1, is characterized in that, the mixture that described mixed enzyme is made up of xanthine oxidase, cellulase, glycosyltransferase.
6. a kind of pharmaceutical composition for the treatment of type Ⅱdiabetes mellitus as described in claim 1 to 5, it is characterized in that preparation method is: by the crude fibre mixture of described composition by weight, phycocyanobilin, patuletin, diosgenin, globulariacitrin, Polyethylene Glycol, pyridoxin, flavonoid glycoside, linoleic acid, 7,4',4'''-Trimethylamentoflavone, nimbecetin, Quercetin, glutamic acid, lysine, tannin, flunarizine, thiamine adopts Mechanical Method mix homogeneously, be placed in super micron mill to pulverize, cross 200-300 mesh sieve, add the mixed enzyme of described composition by weight again, namely sealing cold preservation obtain medical treatment the pharmaceutical composition of type Ⅱdiabetes mellitus.
7. a kind of pharmaceutical composition for the treatment of type Ⅱdiabetes mellitus as described in claim 1 to 6, it is characterized in that adding adjuvant in described pharmaceutical composition: diluent, wetting agent, disintegrating agent, make capsule by granulation, drying, granulate, screening, filling, polishing, packaging.
8. a kind of pharmaceutical composition for the treatment of type Ⅱdiabetes mellitus as described in claim 1 to 6, is characterized in that described diluent is one or several mixing of mannitol, microcrystalline Cellulose, lactose.
9. a kind of pharmaceutical composition for the treatment of type Ⅱdiabetes mellitus as described in claim 1 to 6, is characterized in that described wetting agent is one or several mixing of magnesium stearate, Pulvis Talci, glyceryl monostearate.
10. a kind of pharmaceutical composition for the treatment of type Ⅱdiabetes mellitus as described in claim 1 to 6, is characterized in that described disintegrating agent is one or several mixing of cross-linked cellulose, polyvinylpolypyrrolidone, glycyl Starch Sodium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610038013.7A CN105535947A (en) | 2016-01-20 | 2016-01-20 | Pharmaceutical composition for treating II-type diabetes and preparation method of pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610038013.7A CN105535947A (en) | 2016-01-20 | 2016-01-20 | Pharmaceutical composition for treating II-type diabetes and preparation method of pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105535947A true CN105535947A (en) | 2016-05-04 |
Family
ID=55815824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610038013.7A Pending CN105535947A (en) | 2016-01-20 | 2016-01-20 | Pharmaceutical composition for treating II-type diabetes and preparation method of pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105535947A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138757A (en) * | 2016-08-25 | 2016-11-23 | 陈红专 | A kind of pharmaceutical composition treating type Ⅱdiabetes mellitus and preparation method thereof |
| WO2022115922A1 (en) * | 2020-12-02 | 2022-06-09 | Oxiteno S.A. Indústria E Comércio | Composition and method for enhance uva/uvb resistance of agrochemical formulation, use of the composition, and agrochemical formulation |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1965870A (en) * | 2005-11-18 | 2007-05-23 | 北京天新园医药科技开发有限公司 | Pharmaceutical composition containing ligustrazine and effective component of ginkgo leaf and formulation thereof |
| CN101194921A (en) * | 2006-12-08 | 2008-06-11 | 广州白云山和记黄埔中药有限公司 | Persimmon leaf flavone extract, preparation method and application thereof |
| WO2012071706A1 (en) * | 2010-11-30 | 2012-06-07 | 上海羿康生物科技有限公司 | Pharmaceutical composition for preventing and treating diabetes and its complications |
| CN103275050A (en) * | 2013-05-23 | 2013-09-04 | 南京泽朗农业发展有限公司 | Method for preparing patuletin |
-
2016
- 2016-01-20 CN CN201610038013.7A patent/CN105535947A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1965870A (en) * | 2005-11-18 | 2007-05-23 | 北京天新园医药科技开发有限公司 | Pharmaceutical composition containing ligustrazine and effective component of ginkgo leaf and formulation thereof |
| CN101194921A (en) * | 2006-12-08 | 2008-06-11 | 广州白云山和记黄埔中药有限公司 | Persimmon leaf flavone extract, preparation method and application thereof |
| WO2012071706A1 (en) * | 2010-11-30 | 2012-06-07 | 上海羿康生物科技有限公司 | Pharmaceutical composition for preventing and treating diabetes and its complications |
| CN103275050A (en) * | 2013-05-23 | 2013-09-04 | 南京泽朗农业发展有限公司 | Method for preparing patuletin |
Non-Patent Citations (7)
| Title |
|---|
| 余元勋: "《中国分子神经病学》", 31 August 2015 * |
| 李乐愚: "《糖尿病的中西医治疗》", 30 November 2015 * |
| 杨如哲: "《健康与合理营养》", 30 April 2004 * |
| 班旭升: "《痼疾医要》", 30 September 2012 * |
| 蔡向红: "《湘西主要特色药用植物栽培与利用》", 31 May 2015 * |
| 郑建仙: "《植物活性成分开发》", 30 June 2005 * |
| 金霞: "《更年期科学养生滋补食谱》", 31 March 2009 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138757A (en) * | 2016-08-25 | 2016-11-23 | 陈红专 | A kind of pharmaceutical composition treating type Ⅱdiabetes mellitus and preparation method thereof |
| WO2022115922A1 (en) * | 2020-12-02 | 2022-06-09 | Oxiteno S.A. Indústria E Comércio | Composition and method for enhance uva/uvb resistance of agrochemical formulation, use of the composition, and agrochemical formulation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101919530B (en) | Tea and preparation method thereof | |
| CN101926853B (en) | Medicine composition with function of lowering blood sugar level as well as preparation method and application thereof | |
| CN103734751B (en) | A kind of composite dietary and method for making thereof | |
| CN110623182A (en) | Probiotic plant solid beverage for treating hyperuricemia and gout | |
| CN107080250A (en) | A kind of composition of auxiliary hyperglycemic, beverage and preparation method thereof | |
| CN109010616A (en) | A kind of pure plant preparation for increasing beneficial bacteria of intestinal tract, improving intestinal flora | |
| CN111840363A (en) | Novel natto health-care composition assisting in reducing blood sugar and preparation method and application thereof | |
| CN101607006B (en) | Application of Chinese medicinal composition in preparing medicament for treating hypertension | |
| CN111568948A (en) | Application of mulberry extract in preparing medicine for improving pancreatic islet function | |
| CN105535947A (en) | Pharmaceutical composition for treating II-type diabetes and preparation method of pharmaceutical composition | |
| CN111165709A (en) | Solid beverage with blood sugar control function and preparation method thereof | |
| CN115737757A (en) | A Chinese medicinal composition, YISHENG composition, and its application in treating type II diabetes | |
| JP2005213211A (en) | Agent for inhibiting increase of blood glucose level | |
| CN101491668B (en) | Composition with blood-sugar reducing function and preparation method thereof | |
| CN104644734A (en) | Drug for treating type II diabetes and complications thereof | |
| CN101254200B (en) | Use of cyclocarya paliurus glycoside compounds for preparing medicament for curing diabetes | |
| CN111214641B (en) | Traditional Chinese medicine preparation for treating diabetes | |
| CN110327373B (en) | Application of maggot wine-soaked product in treatment of diabetes | |
| CN110876717A (en) | Preparation method of product capable of stabilizing blood sugar | |
| CN113082106A (en) | Compound composition, application of compound composition in preparation of medicine for treating diabetic complications and medicine for treating diabetic complications | |
| CN101647840B (en) | Chinese herbal medicine composition for controlling metabolic syndrome and preparation method thereof | |
| CN101884723A (en) | Anemarrhena and goldthread composition preparation used for treating diabetes and preparation method thereof | |
| CN104740345B (en) | Treat Chinese medicine composition of diabetes and preparation method thereof | |
| CN108704052A (en) | Hypoglycemic papaya hardship mulberry tablet or capsule and its preparation process | |
| CN1548142A (en) | Medicine for improving sugar tolerance and treating diabetes and its prepn process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160504 |